ArticleOxford medical case reports2026
Citrullinemia type 1 manifesting with a stroke-like episode: a case report.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Citrullinemia type 1 (CTLN1) is a rare inherited disorder caused by mutations in the argininosuccinate synthetase 1 (ASS1) gene, disrupting the urea cycle and leading to toxic ammonia accumulation. It typically presents in newborns with lethargy, vomiting, and poor feeding. Stroke-like neurological presentations are very rare. We report a 19-month-old boy presenting with sudden right-sided weakness, lethargy, and difficulty standing. Laboratory tests revealed elevated ammonia and plasma citrulline, while brain imaging showed extensive cortical and subcortical abnormalities with cerebral edema and midline shift. Genetic testing confirmed heterozygous mutations in the ASS1 gene, diagnosing CTLN1. Prompt treatment with intravenous sodium benzoate, arginine supplementation, and dietary protein restriction led to full neurological recovery over 10 months, with resolution of motor deficits and normalization of biochemical parameters. This case highlights the importance of considering metabolic disorders in acute stroke-like presentations and the value of early biochemical and genetic diagnosis for favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.